Dengue virus vaccine development

Advances in Virus Research

Volumn 88, Issue , 2014, Pages 315-372

  Yauch, Lauren E ^a   Shresta, Sujan ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Dengue fever; Dengue hemorrhagic fever dengue shock syndrome; Dengue virus; Vaccine

Indexed keywords

DENGUE VACCINE; DNA VACCINE; INACTIVATED VACCINE; RECOMBINANT VACCINE; VACCINE;

ARTICLE; DENGUE; DENGUE HEMORRHAGIC FEVER/DENGUE SHOCK SYNDROME; DENGUE VIRUS; DRUG DEVELOPMENT; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION;

DENGUE FEVER; DENGUE HEMORRHAGIC FEVER/DENGUE SHOCK SYNDROME; DENGUE VIRUS; VACCINE;

DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG DISCOVERY; HUMANS; VACCINES, DNA; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 84891086828     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800098-4.00007-6     Document Type: Chapter

References (241)

1. Adalja A.A., Sell T.K., Bouri N., Franco C. Lessons learned during dengue outbreaks in the United States, 2001-2011. Emerging Infectious Diseases 2012, 18(4):608-614.
2. Alvarez M., Rodriguez-Roche R., Bernardo L., Vazquez S., Morier L., Gonzalez D. Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. The American Journal of Tropical Medicine and Hygiene 2006, 75(6):1113-1117.
3. Apt D., Raviprakash K., Brinkman A., Semyonov A., Yang S., Skinner C., et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 2006, 24(3):335-344.
4. Balsitis S.J., Williams K.L., Lachica R., Flores D., Kyle J.L., Mehlhop E., et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathogens 2010, 6(2):e1000790.
5. Bancroft W.H., Scott R.M., Eckels K.H., Hoke C.H., Simms T.E., Jesrani K.D., et al. Dengue virus type 2 vaccine: Reactogenicity and immunogenicity in soldiers. The Journal of Infectious Diseases 1984, 149(6):1005-1010.
6. Bancroft W.H., Top F.H., Eckels K.H., Anderson J.H., McCown J.M., Russell P.K. Dengue-2 vaccine: Virological, immunological, and clinical responses of six yellow fever-immune recipients. Infection and Immunity 1981, 31(2):698-703.
7. Beckett C.G., Tjaden J., Burgess T., Danko J.R., Tamminga C., Simmons M., et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011, 29(5):960-968.
8. Bellanti J.A., Bourke A.T., Buescher E.L., Cadigan F.C., Cole G.A., El Batawi Y., et al. Report of dengue vaccine field trial in the Caribbean, 1963: A collaborative study. Bulletin of the World Health Organization 1966, 35(1):93.
9. Beltramello M., Williams K.L., Simmons C.P., Macagno A., Simonelli L., Quyen N.T., et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host and Microbe 2010, 8(3):271-283.
10. Bhamarapravati N., Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000, 18(Suppl. 2):44-47.
11. Bhamarapravati N., Yoksan S. Study of bivalent dengue vaccine in volunteers. Lancet 1989, 1(8646):1077.
12. Bhamarapravati N., Yoksan S., Chayaniyayothin T., Angsubphakorn S., Bunyaratvej A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): Clinical, immunological and biological responses in adult volunteers. Bulletin of the World Health Organization 1987, 65(2):189-195.
13. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496(7446):504-507.
14. Bielefeldt-Ohmann H., Beasley D.W., Fitzpatrick D.R., Aaskov J.G. Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system. The Journal of General Virology 1997, 78(Pt. 11):2723-2733.
15. Blaney J.E., Hanson C.T., Firestone C.Y., Hanley K.A., Murphy B.R., Whitehead S.S. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. American Journal of Tropical Medicine and Hygiene 2004, 71(6):811-821.
16. Blaney J.E., Hanson C.T., Hanley K.A., Murphy B.R., Whitehead S.S. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infectious Diseases 2004, 4:39.
17. Blaney J.E., Johnson D.H., Firestone C.Y., Hanson C.T., Murphy B.R., Whitehead S.S. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. Journal of Virology 2001, 75(20):9731-9740.
18. Blaney J.E., Matro J.M., Murphy B.R., Whitehead S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. Journal of Virology 2005, 79(9):5516-5528.
19. Blaney J.E., Sathe N.S., Goddard L., Hanson C.T., Romero T.A., Hanley K.A., et al. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4. Vaccine 2008, 26(6):817-828.
20. Blaney J.E., Sathe N.S., Hanson C.T., Firestone C.Y., Murphy B.R., Whitehead S.S. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. Virology Journal 2007, 4:23.
21. Blanton R.E., Silva L.K., Morato V.G., Parrado A.R., Dias J.P., Melo P.R., et al. Genetic ancestry and income are associated with dengue hemorrhagic fever in a highly admixed population. European Journal of Human Genetics 2008, 16(6):762-765.
22. Brandler S., Brown N., Ermak T.H., Mitchell F., Parsons M., Zhang Z., et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. The American Journal of Tropical Medicine and Hygiene 2005, 72(1):74-81.
23. Bray M., Lai C.J. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proceedings of the National Academy of Sciences of the United States of America 1991, 88(22):10342-10346.
24. Bray M., Men R., Lai C.J. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. Journal of Virology 1996, 70(6):4162-4166.
25. Bray M., Zhao B.T., Markoff L., Eckels K.H., Chanock R.M., Lai C.J. Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis. Journal of Virology 1989, 63(6):2853-2856.
26. Brewoo J.N., Kinney R.M., Powell T.D., Arguello J.J., Silengo S.J., Partidos C.D., et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 2012, 30(8):1513-1520.
27. Brien J.D., Austin S.K., Sukupolvi-Petty S., O'Brien K.M., Johnson S., Fremont D.H., et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. Journal of Virology 2010, 84(20):10630-10643.
28. Burke D.S., Nisalak A., Johnson D.E., Scott R.M. A prospective study of dengue infections in Bangkok. The American Journal of Tropical Medicine and Hygiene 1988, 38(1):172-180.
29. Butrapet S., Huang C.Y., Pierro D.J., Bhamarapravati N., Gubler D.J., Kinney R.M. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. Journal of Virology 2000, 74(7):3011-3019.
30. Capeding R.Z., Luna I.A., Bomasang E., Lupisan S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines. Vaccine 2011, 29(22):3863-3872.
31. Carey D.E., Myers R.M., Rodrigues F.M. Two episodes of dengue fever, caused by types 4 and 1 viruses, in an individual previously immunized against yellow fever. The American Journal of Tropical Medicine and Hygiene 1965, 14:448-450.
32. Chambers T.J., Nestorowicz A., Mason P.W., Rice C.M. Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties. Journal of Virology 1999, 73(4):3095-3101.
33. Chen L., Ewing D., Subramanian H., Block K., Rayner J., Alterson K.D., et al. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. Journal of Virology 2007, 81(21):11634-11639.
34. Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., et al. Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28(15):2705-2715.
35. Clyde K., Kyle J.L., Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. Journal of Virology 2006, 80(23):11418-11431.
36. Cole G.A., Wisseman C.L. Pathogenesis of type 1 dengue virus infection in suckling, weanling and adult mice. 1. The relation of virus replication to interferon and antibody formation. American Journal of Epidemiology 1969, 89(6):669-680.
37. Coller B.A., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29(42):7267-7275.
38. Costa S.M., Azevedo A.S., Paes M.V., Sarges F.S., Freire M.S., Alves A.M. DNA vaccines against dengue virus based on the ns1 gene: The influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. Virology 2007, 358(2):413-423.
39. Costa S.M., Paes M.V., Barreto D.F., Pinhao A.T., Barth O.M., Queiroz J.L., et al. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine 2006, 24(2):195-205.
40. Crill W.D., Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. Journal of Virology 2001, 75(16):7769-7773.
41. Danko J.R., Beckett C.G., Porter K.R. Development of dengue DNA vaccines. Vaccine 2011, 29(42):7261-7266.
42. de Alwis R., Beltramello M., Messer W.B., Sukupolvi-Petty S., Wahala W.M., Kraus A., et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Neglected Tropical Diseases 2011, 5(6):e1188.
43. de Alwis R., Smith S.A., Olivarez N.P., Messer W.B., Huynh J.P., Wahala W.M., et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(19):7439-7444.
44. Dejnirattisai W., Jumnainsong A., Onsirisakul N., Fitton P., Vasanawathana S., Limpitikul W., et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328(5979):745-748.
45. Delenda C., Staropoli I., Frenkiel M.P., Cabanie L., Deubel V. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: Processing in insect cells and immunogenic properties in mice. The Journal of General Virology 1994, 75(Pt. 7):1569-1578.
46. Dharakul T., Kurane I., Bhamarapravati N., Yoksan S., Vaughn D.W., Hoke C.H., et al. Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine. The Journal of Infectious Diseases 1994, 170(1):27-33.
47. Diallo M., Ba Y., Sall A.A., Diop O.M., Ndione J.A., Mondo M., et al. Amplification of the sylvatic cycle of dengue virus type 2, Senegal, 1999-2000: Entomologic findings and epidemiologic considerations. Emerging Infectious Diseases 2003, 9(3):362-367.
48. Diamond M.S., Shrestha B., Marri A., Mahan D., Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. Journal of Virology 2003, 77(4):2578-2586.
49. Dorrance W.R., Frankel J.W., Gordon I., Patterson P.R., Schlesinger R.W., Winter J.W. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. Journal of Immunology 1956, 77(5):352-364.
50. Drexler I., Staib C., Sutter G. Modified vaccinia virus Ankara as antigen delivery system: How can we best use its potentialα. Current Opinion in Biotechnology 2004, 15(6):506-512.
51. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. The American Journal of Tropical Medicine and Hygiene 2001, 65(5):405-413.
52. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Elwood D., Larsson C.J., Lindow J.C., et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial. The Journal of Infectious Diseases 2013, 207(6):957-965.
53. Durbin A.P., McArthur J., Marron J.A., Blaney J.E., Thumar B., Wanionek K., et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Human Vaccines 2006, 2(4):167-173.
54. Durbin A.P., McArthur J.H., Marron J.A., Blaney J.E., Thumar B., Wanionek K., et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Human Vaccines 2006, 2(6):255-260.
55. Durbin A.P., Schmidt A., Elwood D., Wanionek K.A., Lovchik J., Thumar B., et al. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: Implications for vaccination of populations in areas where dengue is endemic. The Journal of Infectious Diseases 2011, 203(3):327-334.
56. Durbin A.P., Whitehead S.S. The dengue human challenge model: Has the time come to accept this challengeα. The Journal of Infectious Diseases 2013, 207(5):697-699.
57. Durbin A.P., Whitehead S.S., McArthur J., Perreault J.R., Blaney J.E., Thumar B., et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. The Journal of Infectious Diseases 2005, 191(5):710-718.
58. Durbin A.P., Whitehead S.S., Shaffer D., Elwood D., Wanionek K., Thumar B., et al. A single dose of the DENV-1 candidate vaccine rDEN1Delta30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. PLoS Neglected Tropical Diseases 2011, 5(8):e1267.
59. Eckels K.H., Brandt W.E., Harrison V.R., McCown J.M., Russell P.K. Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. Infection and Immunity 1976, 14(5):1221-1227.
60. Eckels K.H., Dubois D.R., Summers P.L., Schlesinger J.J., Shelly M., Cohen S., et al. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: Evidence of priming and partial protection. The American Journal of Tropical Medicine and Hygiene 1994, 50(4):472-478.
61. Eckels K.H., Harrison V.R., Summers P.L., Russell P.K. Dengue-2 vaccine: Preparation from a small-plaque virus clone. Infection and Immunity 1980, 27(1):175-180.
62. Eckels K.H., Scott R.M., Bancroft W.H., Brown J., Dubois D.R., Summers P.L., et al. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. The American Journal of Tropical Medicine and Hygiene 1984, 33(4):684-689.
63. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. The American Journal of Tropical Medicine and Hygiene 2003, 69(6 Suppl.):48-60.
64. Endy T.P., Nisalak A., Chunsuttitwat S., Vaughn D.W., Green S., Ennis F.A., et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. The Journal of Infectious Diseases 2004, 189(6):990-1000.
65. Falgout B., Bray M., Schlesinger J.J., Lai C.J. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. Journal of Virology 1990, 64(9):4356-4363.
66. Fonseca B.A., Khoshnood K., Shope R.E., Mason P.W. Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli trpE gene. The American Journal of Tropical Medicine and Hygiene 1991, 44(5):500-508.
67. Fonseca B.A., Pincus S., Shope R.E., Paoletti E., Mason P.W. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 1994, 12(3):279-285.
68. Garcia G., Arango M., Perez A.B., Fonte L., Sierra B., Rodriguez-Roche R., et al. Antibodies from patients with dengue viral infection mediate cellular cytotoxicity. Journal of Clinical Virology 2006, 37(1):53-57.
69. Goncalvez A.P., Engle R.E., St Claire M., Purcell R.H., Lai C.J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(22):9422-9427.
70. Groene W.S., Shaw R.D. Psoralen preparation of antigenically intact noninfectious rotavirus particles. Journal of Virological Methods 1992, 38(1):93-102.
71. Gubler D.J. The economic burden of dengue. The American Journal of Tropical Medicine and Hygiene 2012, 86(5):743-744.
72. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. Journal of Virology 2001, 75(16):7290-7304.
73. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Human Vaccines 2006, 2(2):60-67.
74. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. Journal of Virology 2004, 78(9):4761-4775.
75. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. Journal of Virology 2000, 74(12):5477-5485.
76. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: Immunology, application, and optimization. Annual Review of Immunology 2000, 18:927-974.
77. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. The American Journal of Tropical Medicine and Hygiene 2009, 80(2):302-311.
78. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008, 26(45):5712-5721.
79. Guzman M.G., Kouri G., Martinez E., Bravo J., Riveron R., Soler M., et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bulletin of the Pan American Health Organization 1987, 21(3):270-279.
80. Guzman M.G., Kouri G., Valdes L., Bravo J., Alvarez M., Vazques S., et al. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. American Journal of Epidemiology 2000, 152(9):793-799. discussion 804.
81. Guzman M.G., Kouri G., Valdes L., Bravo J., Vazquez S., Halstead S.B. Enhanced severity of secondary dengue-2 infections: Death rates in 1981 and 1997 Cuban outbreaks. Revista Panamericana de Salud Publica 2002, 11(4):223-227.
82. Guzman M.G., Rodriguez R., Hermida L., Alvarez M., Lazo L., Mune M., et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. The American Journal of Tropical Medicine and Hygiene 2003, 69(2):129-134.
83. Halstead S.B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. Journal of Infectious Diseases 1979, 140(4):527-533.
84. Halstead S.B. Pathogenesis of dengue: Challenges to molecular biology. Science 1988, 239(4839):476-481.
85. Halstead S.B. Dengue. Lancet 2007, 370(9599):1644-1652.
86. Halstead S.B., Casals J., Shotwell H., Palumbo N. Studies on the immunization of monkeys against dengue. I. Protection derived from single and sequential virus infections. The American Journal of Tropical Medicine and Hygiene 1973, 22(3):365-374.
87. Halstead S.B., Eckels K.H., Putvatana R., Larsen L.K., Marchette N.J. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells. The American Journal of Tropical Medicine and Hygiene 1984, 33(4):679-683.
88. Halstead S.B., Marchette N.J. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: Studies at the University of Hawaii. The American Journal of Tropical Medicine and Hygiene 2003, 69(6 Suppl.):5-11.
89. Halstead S.B., Nimmannitya S., Cohen S.N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale Journal of Biology and Medicine 1970, 42(5):311-328.
90. Halstead S.B., O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977, 265(5596):739-741.
91. Halstead S.B., O'Rourke E.J., Allison A.C. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. Journal of Experimental Medicine 1977, 146(1):218-229.
92. Halstead S.B., Palumbo N.E. Studies on the immunization of monkeys against dengue. II. Protection following inoculation of combinations of viruses. The American Journal of Tropical Medicine and Hygiene 1973, 22(3):375-381.
93. Halstead S.B., Streit T.G., Lafontant J.G., Putvatana R., Russell K., Sun W., et al. Haiti: Absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. The American Journal of Tropical Medicine and Hygiene 2001, 65(3):180-183.
94. Hanley K.A., Lee J.J., Blaney J.E., Murphy B.R., Whitehead S.S. Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. Journal of Virology 2002, 76(2):525-531.
95. Hanley K.A., Manlucu L.R., Manipon G.G., Hanson C.T., Whitehead S.S., Murphy B.R., et al. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine 2004, 22(25-26):3440-3448.
96. Harrison V.R., Eckels K.H., Sagartz J.W., Russell P.K. Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates. Infection and Immunity 1977, 18(1):151-156.
97. Heinz F.X., Auer G., Stiasny K., Holzmann H., Mandl C., Guirakhoo F., et al. The interactions of the flavivirus envelope proteins: Implications for virus entry and release. Archives of Virology. Supplementum 1994, 9:339-348.
98. Hermida L., Bernardo L., Martin J., Alvarez M., Prado I., Lopez C., et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006, 24(16):3165-3171.
99. Hermida L., Rodriguez R., Lazo L., Silva R., Zulueta A., Chinea G., et al. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. Journal of Virological Methods 2004, 115(1):41-49.
100. Higgs S., Vanlandingham D.L., Klingler K.A., McElroy K.L., McGee C.E., Harrington L., et al. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. The American Journal of Tropical Medicine and Hygiene 2006, 75(5):986-993.
101. Hoke C.H., Malinoski F.J., Eckels K.H., Scott R.M., Dubois D.R., Summers P.L., et al. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. The American Journal of Tropical Medicine and Hygiene 1990, 43(2):219-226.
102. Holman D.H., Wang D., Raviprakash K., Raja N.U., Luo M., Zhang J., et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clinical and Vaccine Immunology 2007, 14(2):182-189.
103. Hotta S. Experimental studies on dengue. I. Isolation, identification and modification of the virus. The Journal of Infectious Diseases 1952, 90(1):1-9.
104. Huang C.Y., Butrapet S., Pierro D.J., Chang G.J., Hunt A.R., Bhamarapravati N., et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. Journal of Virology 2000, 74(7):3020-3028.
105. Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. Journal of Virology 2003, 77(21):11436-11447.
106. Imoto J., Konishi E. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 2007, 25(6):1076-1084.
107. Innis B.L., Eckels K.H., Kraiselburd E., Dubois D.R., Meadors G.F., Gubler D.J., et al. Virulence of a live dengue virus vaccine candidate: A possible new marker of dengue virus attenuation. The Journal of Infectious Diseases 1988, 158(4):876-880.
108. Jaiswal S., Khanna N., Swaminathan S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. Journal of Virology 2003, 77(23):12907-12913.
109. Jelinek T., Muhlberger N., Harms G., Corachan M., Grobusch M.P., Knobloch J., et al. Epidemiology and clinical features of imported dengue fever in Europe: Sentinel surveillance data from TropNetEurop. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2002, 35(9):1047-1052.
110. Johnson B.W., Chambers T.V., Crabtree M.B., Guirakhoo F., Monath T.P., Miller B.R. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. The American Journal of Tropical Medicine and Hygiene 2004, 70(1):89-97.
111. Johnson A.J., Roehrig J.T. New mouse model for dengue virus vaccine testing. Journal of Virology 1999, 73(1):783-786.
112. Kanesa-thasan N., Sun W., Kim-Ahn G., Van Albert S., Putnak J.R., King A., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001, 19(23-24):3179-3188.
113. Kaufman B.M., Summers P.L., Dubois D.R., Cohen W.H., Gentry M.K., Timchak R.L., et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. The American Journal of Tropical Medicine and Hygiene 1989, 41(5):576-580.
114. Kaufman B.M., Summers P.L., Dubois D.R., Eckels K.H. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. The American Journal of Tropical Medicine and Hygiene 1987, 36(2):427-434.
115. Kelly E.P., Greene J.J., King A.D., Innis B.L. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 2000, 18(23):2549-2559.
116. Khanam S., Pilankatta R., Khanna N., Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009, 27(43):6011-6021.
117. Khanam S., Rajendra P., Khanna N., Swaminathan S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnology 2007, 7:10.
118. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23(25):3256-3263.
119. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24(9):1238-1241.
120. Kliks S.C., Nimmanitya S., Nisalak A., Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. The American Journal of Tropical Medicine and Hygiene 1988, 38(2):411-419.
121. Kochel T.J., Raviprakash K., Hayes C.G., Watts D.M., Russell K.L., Gozalo A.S., et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000, 18(27):3166-3173.
122. Kochel T., Wu S.J., Raviprakash K., Hobart P., Hoffman S., Porter K., et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997, 15(5):547-552.
123. Konishi E., Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 2002, 20(7-8):1058-1067.
124. Konishi E., Kosugi S., Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 2006, 24(12):2200-2207.
125. Konishi E., Terazawa A., Fujii A. Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. Vaccine 2003, 21(25-26):3713-3720.
126. Konishi E., Yamaoka M., Kurane I., Mason P.W. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 2000, 18(11-12):1133-1139.
127. Koraka P., Benton S., van Amerongen G., Stittelaar K.J., Osterhaus A.D. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques. Vaccine 2007, 25(29):5409-5416.
128. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., et al. Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion. Cell 2002, 108(5):717-725.
129. Kuwahara M., Konishi E. Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens. Clinical and Vaccine Immunology 2010, 17(10):1560-1566.
130. Kyle J.L., Harris E. Global spread and persistence of dengue. Annual Review of Microbiology 2008, 62:71-92.
131. Lanata C.F., Andrade T., Gil A.I., Terrones C., Valladolid O., Zambrano B., et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru. Vaccine 2012, 30(41):5935-5941.
132. Laoprasopwattana K., Libraty D.H., Endy T.P., Nisalak A., Chunsuttiwat S., Ennis F.A., et al. Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: Potential involvement in early control of viral replication. The Journal of Infectious Diseases 2007, 195(8):1108-1116.
133. Lu Y., Raviprakash K., Leao I.C., Chikhlikar P.R., Ewing D., Anwar A., et al. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine 2003, 21(17-18):2178-2189.
134. MacDonald G.H., Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. Journal of Virology 2000, 74(2):914-922.
135. Mahoney R.T., Francis D.P., Frazatti-Gallina N.M., Precioso A.R., Raw I., Watler P., et al. Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine 2012, 30(32):4892-4896.
136. Mangada M.M., Rothman A.L. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. Journal of Immunology 2005, 175(4):2676-2683.
137. Mantel N., Girerd Y., Geny C., Bernard I., Pontvianne J., Lang J., et al. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 2011, 29(38):6629-6635.
138. Marchette N.J., Dubois D.R., Larsen L.K., Summers P.L., Kraiselburd E.G., Gubler D.J., et al. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies. The American Journal of Tropical Medicine and Hygiene 1990, 43(2):212-218.
139. Marchette N.J., Halstead S.B., Falkler W.A., Stenhouse A., Nash D. Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. The Journal of Infectious Diseases 1973, 128(1):23-30.
140. Mason P.W., Zugel M.U., Semproni A.R., Fournier M.J., Mason T.L. The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coli. The Journal of General Virology 1990, 71(Pt. 9):2107-2114.
141. Maves R.C., Castillo Ore R.M., Porter K.R., Kochel T.J. Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice. Clinical and Vaccine Immunology 2010, 17(2):304-306.
142. Maves R.C., Ore R.M., Porter K.R., Kochel T.J. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine 2011, 29(15):2691-2696.
143. McArthur J.H., Durbin A.P., Marron J.A., Wanionek K.A., Thumar B., Pierro D.J., et al. Phase I clinical evaluation of rDEN4Delta30-200,201: A live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. The American Journal of Tropical Medicine and Hygiene 2008, 79(5):678-684.
144. McKee K.T., Bancroft W.H., Eckels K.H., Redfield R.R., Summers P.L., Russell P.K. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. The American Journal of Tropical Medicine and Hygiene 1987, 36(2):435-442.
145. Megret F., Hugnot J.P., Falconar A., Gentry M.K., Morens D.M., Murray J.M., et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 1992, 187(2):480-491.
146. Men R., Bray M., Clark D., Chanock R.M., Lai C.J. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. Journal of Virology 1996, 70(6):3930-3937.
147. Men R.H., Bray M., Lai C.J. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. Journal of Virology 1991, 65(3):1400-1407.
148. Men R., Wyatt L., Tokimatsu I., Arakaki S., Shameem G., Elkins R., et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 2000, 18(27):3113-3122.
149. Monath T.P., Myers G.A., Beck R.A., Knauber M., Scappaticci K., Pullano T., et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys. Biologicals: Journal of the International Association of Biological Standardization 2005, 33(3):131-144.
150. Mongkolsapaya J., Dejnirattisai W., Xu X.N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nature Medicine 2003, 9(7):921-927.
151. Mongkolsapaya J., Duangchinda T., Dejnirattisai W., Vasanawathana S., Avirutnan P., Jairungsri A., et al. T cell responses in dengue hemorrhagic fever: Are cross-reactive T cells suboptimalα. Journal of Immunology 2006, 176(6):3821-3829.
152. Morens D.M., Halstead S.B., Marchette N.J. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microbial Pathogenesis 1987, 3(4):231-237.
153. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. The Journal of Infectious Diseases 2010, 201(3):370-377.
154. Mukhopadhyay S., Kuhn R.J., Rossmann M.G. A structural perspective of the flavivirus life cycle. Nature Reviews. Microbiology 2005, 3(1):13-22.
155. Muller D.A., Young P.R. The flavivirus NS1 protein: Molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Research 2013, 98(2):192-208.
156. Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annual Review of Immunology 2011, 29:587-619.
157. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nature Medicine 2005, 11(5):522-530.
158. Onlamoon N., Noisakran S., Hsiao H.M., Duncan A., Villinger F., Ansari A.A., et al. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 2010, 115(9):1823-1834.
159. Osorio J.E., Brewoo J.N., Silengo S.J., Arguello J., Moldovan I.R., Tary-Lehmann M., et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. The American Journal of Tropical Medicine and Hygiene 2011, 84(6):978-987.
160. Osorio J.E., Huang C.Y., Kinney R.M., Stinchcomb D.T. Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011, 29(42):7251-7260.
161. Pierson T.C., Xu Q., Nelson S., Oliphant T., Nybakken G.E., Fremont D.H., et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host and Microbe 2007, 1(2):135-145.
162. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G.H. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: Randomized controlled phase 1 trial of safety and immunogenicity. The Pediatric Infectious Disease Journal 2010, 30(1):e9-e17.
163. Porter K.R., Kochel T.J., Wu S.J., Raviprakash K., Phillips I., Hayes C.G. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Archives of Virology 1998, 143(5):997-1003.
164. Prestwood T.R., Prigozhin D.M., Sharar K.L., Zellweger R.M., Shresta S. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. Journal of Virology 2008, 82(17):8411-8421.
165. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nature Immunology 2011, 12(6):509-517.
166. Putnak R., Barvir D.A., Burrous J.M., Dubois D.R., D'Andrea V.M., Hoke C.H., et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys. The Journal of Infectious Diseases 1996, 174(6):1176-1184.
167. Putnak R., Cassidy K., Conforti N., Lee R., Sollazzo D., Truong T., et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. The American Journal of Tropical Medicine and Hygiene 1996, 55(5):504-510.
168. Putnak R., Feighny R., Burrous J., Cochran M., Hackett C., Smith G., et al. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. The American Journal of Tropical Medicine and Hygiene 1991, 45(2):159-167.
169. Qiao M., Shaw D., Forrat R., Wartel-Tram A., Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. The American Journal of Tropical Medicine and Hygiene 2011, 85(4):724-731.
170. Raja N.U., Holman D.H., Wang D., Raviprakash K., Juompan L.Y., Deitz S.B., et al. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. The American Journal of Tropical Medicine and Hygiene 2007, 76(4):743-751.
171. Ramanathan M.P., Kuo Y.C., Selling B.H., Li Q., Sardesai N.Y., Kim J.J., et al. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine 2009, 27(46):6444-6453.
172. Raviprakash K., Apt D., Brinkman A., Skinner C., Yang S., Dawes G., et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006, 353(1):166-173.
173. Raviprakash K., Ewing D., Simmons M., Porter K.R., Jones T.R., Hayes C.G., et al. Needle-free biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 2003, 315(2):345-352.
174. Raviprakash K., Kochel T.J., Ewing D., Simmons M., Phillips I., Hayes C.G., et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000, 18(22):2426-2434.
175. Raviprakash K., Marques E., Ewing D., Lu Y., Phillips I., Porter K.R., et al. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 2001, 290(1):74-82.
176. Raviprakash K., Porter K.R., Kochel T.J., Ewing D., Simmons M., Phillips I., et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. The Journal of General Virology 2000, 81(Pt. 7):1659-1667.
177. Raviprakash K., Wang D., Ewing D., Holman D.H., Block K., Woraratanadharm J., et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. Journal of Virology 2008, 82(14):6927-6934.
178. Rey F.A., Heinz F.X., Mandl C., Kunz C., Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995, 375(6529):291-298.
179. Rico-Hesse R. Dengue virus evolution and virulence models. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2007, 44(11):1462-1466.
180. Robert Putnak J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23(35):4442-4452.
181. Roehrig J.T. Antigenic structure of flavivirus proteins. Advances in Virus Research 2003, 59:141-175.
182. Rothman A.L., Kanesa-thasan N., West K., Janus J., Saluzzo J.F., Ennis F.A. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 2001, 19(32):4694-4699.
183. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: Role of serotype concentration, ratio, and multiple doses. The American Journal of Tropical Medicine and Hygiene 2002, 66(3):264-272.
184. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. The Pediatric Infectious Disease Journal 2004, 23(2):99-109.
185. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 2012, 380(9853):1559-1567.
186. Sabin A.B. Research on dengue during World War II. The American Journal of Tropical Medicine and Hygiene 1952, 1(1):30-50.
187. Sabin A.B., Schlesinger R.W. Production of immunity to dengue with virus modified by propagation in mice. Science 1945, 101(2634):640-642.
188. Sanchez V., Gimenez S., Tomlinson B., Chan P.K., Thomas G.N., Forrat R., et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006, 24(23):4914-4926.
189. Sangkawibha N., Rojanasuphot S., Ahandrik S., Viriyapongse S., Jatanasen S., Salitul V., et al. Risk factors in dengue shock syndrome: A prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. American Journal of Epidemiology 1984, 120(5):653-669.
190. Scherer W.F., Russell P.K., Rosen L., Casals J., Dickerman R.W. Experimental infection of chimpanzees with dengue viruses. The American Journal of Tropical Medicine and Hygiene 1978, 27(3):590-599.
191. Scott R.M., Eckels K.H., Bancroft W.H., Summers P.L., McCown J.M., Anderson J.H., et al. Dengue 2 vaccine: Dose response in volunteers in relation to yellow fever immune status. The Journal of Infectious Diseases 1983, 148(6):1055-1060.
192. Scott R.M., Nisalak A., Eckels K.H., Tingpalapong M., Harrison V.R., Gould D.J., et al. Dengue-2 vaccine: Viremia and immune responses in rhesus monkeys. Infection and Immunity 1980, 27(1):181-186.
193. Shrestha B., Brien J.D., Sukupolvi-Petty S., Austin S.K., Edeling M.A., Kim T., et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathogens 2010, 6(4):e1000823.
194. Simasathien S., Thomas S.J., Watanaveeradej V., Nisalak A., Barberousse C., Innis B.L., et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. The American Journal of Tropical Medicine and Hygiene 2008, 78(3):426-433.
195. Simmons M., Burgess T., Lynch J., Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010, 396(2):280-288.
196. Simmons C.P., Dong T., Chau N.V., Dung N.T., Chau T.N., Thao le T.T., et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. Journal of Virology 2005, 79(9):5665-5675.
197. Simmons M., Murphy G.S., Hayes C.G. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. The American Journal of Tropical Medicine and Hygiene 2001, 65(2):159-161.
198. Simmons M., Murphy G.S., Kochel T., Raviprakash K., Hayes C.G. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. The American Journal of Tropical Medicine and Hygiene 2001, 65(5):420-426.
199. Simmons M., Nelson W.M., Wu S.J., Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. The American Journal of Tropical Medicine and Hygiene 1998, 58(5):655-662.
200. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. Journal of Virology 2006, 80(19):9577-9585.
201. Sugrue R.J., Fu J., Howe J., Chan Y.C. Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. The Journal of General Virology 1997, 78(Pt. 8):1861-1866.
202. Sukupolvi-Petty S., Austin S.K., Engle M., Brien J.D., Dowd K.A., Williams K.L., et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. Journal of Virology 2010, 84(18):9227-9239.
203. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. Journal of Virology 2007, 81(23):12816-12826.
204. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Human Vaccines 2009, 5(1):33-40.
205. Sun W., Eckels K.H., Putnak J.R., Lyons A.G., Thomas S.J., Vaughn D.W., et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. The Journal of Infectious Diseases 2013, 207(5):700-708.
206. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. The American Journal of Tropical Medicine and Hygiene 2003, 69(6 Suppl.):24-31.
207. Tan G.K., Ng J.K., Trasti S.L., Schul W., Yip G., Alonso S. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Neglected Tropical Diseases 2010, 4(4):e672.
208. Tatsis N., Ertl H.C. Adenoviruses as vaccine vectors. Molecular Therapy: The Journal of the American Society of Gene Therapy 2004, 10(4):616-629.
209. Thomas S.J., Eckels K.H., Carletti I., De La Barrera R., Dessy F., Fernandez S., et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. The American Journal of Tropical Medicine and Hygiene 2013, 88(1):73-88.
210. Thompson J.M., Whitmore A.C., Konopka J.L., Collier M.L., Richmond E.M., Davis N.L., et al. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(10):3722-3727.
211. Timofeev A.V., Butenko V.M., Stephenson J.R. Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus. Virus Genes 2004, 28(1):85-97.
212. Troyer J.M., Hanley K.A., Whitehead S.S., Strickman D., Karron R.A., Durbin A.P., et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. The American Journal of Tropical Medicine and Hygiene 2001, 65(5):414-419.
213. Valdes I., Bernardo L., Gil L., Pavon A., Lazo L., Lopez C., et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009, 394(2):249-258.
214. Valdes I., Hermida L., Martin J., Menendez T., Gil L., Lazo L., et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2009, 27(7):995-1001.
215. van Der Most R.G., Murali-Krishna K., Ahmed R., Strauss J.H. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: Quantitation of the dengue virus-specific CD8 T-cell response. Journal of Virology 2000, 74(17):8094-8101.
216. van der Schaar H.M., Rust M.J., Waarts B.L., van der Ende-Metselaar H., Kuhn R.J., Wilschut J., et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. Journal of Virology 2007, 81(21):12019-12028.
217. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. The Journal of Infectious Diseases 2000, 181(1):2-9.
218. Vaughn D.W., Hoke C.H., Yoksan S., LaChance R., Innis B.L., Rice R.M., et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 1996, 14(4):329-336.
219. Velzing J., Groen J., Drouet M.T., van Amerongen G., Copra C., Osterhaus A.D., et al. Induction of protective immunity against Dengue virus type 2: Comparison of candidate live attenuated and recombinant vaccines. Vaccine 1999, 17(11-12):1312-1320.
220. Wahala W.M., Donaldson E.F., de Alwis R., Accavitti-Loper M.A., Baric R.S., de Silva A.M. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathogens 2010, 6(3):e1000821.
221. Watanaveeradej V., Simasathien S., Nisalak A., Endy T.P., Jarman R.G., Innis B.L., et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. The American Journal of Tropical Medicine and Hygiene 2011, 85(2):341-351.
222. Weiskopf D., Angelo M.A., de Azeredo E.L., Sidney J., Greenbaum J.A., Fernando A.N., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(22):E2046-E2053.
223. Weiskopf D., Yauch L.E., Angelo M.A., John D.V., Greenbaum J.A., Sidney J., et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. Journal of Immunology 2011, 187(8):4268-4279.
224. White L.J., Parsons M.M., Whitmore A.C., Williams B.M., de Silva A., Johnston R.E. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. Journal of Virology 2007, 81(19):10329-10339.
225. White L.J., Sariol C.A., Mattocks M.D., Wahala M.P.B.W., Yingsiwaphat V., Collier M.L., et al. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. Journal of Virology 2013, 87(6):3409-3424.
226. Whitehead S.S., Falgout B., Hanley K.A., Blaney Jr J.E., Markoff L., Murphy B.R. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. Journal of Virology 2003, 77(2):1653-1657.
227. Whitehead S.S., Hanley K.A., Blaney J.E., Gilmore L.E., Elkins W.R., Murphy B.R. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003, 21(27-30):4307-4316.
228. WHO Dengue: Guidelines for diagnosis, treatment, prevention and control (WHO/HTM/NTD/DEN/2009.1 ed.) 2009, World Health Organization (WHO) Press, Geneva, Switzerland.
229. WHO Guidelines on the quality, safety, and efficacy of dengue tetravalent vaccines (live, attenuated) 2011.
230. WHO Initiative for Vaccine Research., & World Health Organization. Dept. of Immunization Vaccines and Biologicals Guidelines for the clinical evaluation of dengue vaccines in endemic areas 2008, World Health Organization, Geneva.
231. Wolfe N.D., Kilbourn A.M., Karesh W.B., Rahman H.A., Bosi E.J., Cropp B.C., et al. Sylvatic transmission of arboviruses among Bornean orangutans. The American Journal of Tropical Medicine and Hygiene 2001, 64(5-6):310-316.
232. Wu S.F., Liao C.L., Lin Y.L., Yeh C.T., Chen L.K., Huang Y.F., et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 2003, 21(25-26):3919-3929.
233. Yauch L.E., Prestwood T.R., May M.M., Morar M.M., Zellweger R.M., Peters B., et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. Journal of Immunology 2010, 185(9):5405-5416.
234. Yauch L.E., Zellweger R.M., Kotturi M.F., Qutubuddin A., Sidney J., Peters B., et al. A protective role for dengue virus-specific CD8+ T cells. Journal of Immunology 2009, 182(8):4865-4873.
235. Zellweger R., Miller R., Eddy W.E., White L., Johnston R., Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathogens 2013, 9(10):e1003723.
236. Zellweger R.M., Prestwood T.R., Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host and Microbe 2010, 7(2):128-139.
237. Zhang Y.M., Hayes E.P., McCarty T.C., Dubois D.R., Summers P.L., Eckels K.H., et al. Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. Journal of Virology 1988, 62(8):3027-3031.
238. Zhang S., Liang M., Gu W., Li C., Miao F., Wang X., et al. Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virology Journal 2011, 8:333.
239. Zhao B.T., Prince G., Horswood R., Eckels K., Summers P., Chanock R., et al. Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus. Journal of Virology 1987, 61(12):4019-4022.
240. Zheng Q., Fan D., Gao N., Chen H., Wang J., Ming Y., et al. Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection. Vaccine 2011, 29(4):763-771.
241. Zompi S., Harris E. Animal models of dengue virus infection. Viruses 2012, 4(1):62-82.